In humans, a specialized mRNA translation circuit predetermines the competence for heart formation at an early stage of embryonic development, a research team at the Center for Molecular Medicine ...

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, ...

Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists—so far. A new multi-chamber organoid ...

In the left part can be seen multi-omics analysis suggested some proteins (histone / non-histone), protein lactylation, and genes change significantly at different developmental stages (1 w [week], 6 ...

Using a combination for spatial, single-cell transcriptomics and imaging data from 36 hearts, scientists from the KTH Royal Institute of Technology and their collaborators have come up with what they ...

Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists – so far. A new multi-chamber organoid ...

Infants born with Down syndrome, the genetic condition caused by an extra copy of chromosome 21, or trisomy 21, are highly predisposed to congenital heart defects. It is estimated that nearly half of ...

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the shortcomings of existing experimental models. Traditional ...

A crucial new mechanism that helps explain how the heart’s major blood vessels form during early development – and how disruptions to this process can lead to serious congenital heart defects – has ...

Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward ...